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EXPLORING A ROLE FOR THE SERINE PROTEASE PACE4 IN PAIN
ASSOCIATED WITH EXPERIMENTAL OA
R.E. Miller, P.B. Tran, S. Ishihara, R. Das, A.-M. Malfait. Rush Univ. Med.
Ctr., Chicago, IL, United States
Purpose: PACE4 belongs to the family of proprotein convertases that
process precursor proteins into biologically active products through
cleavage at paired basic amino acid processing sites, which is essential for
proteolytic maturation of a wide variety of proteins, including growth
factors, hormones, neuropeptides and zymogens. PACE4 is broadly
expressed throughout the body, including high expression in the central
nervous system. PACE4 reportedly removes the prodomain of pro-
ADAMTS-4 and pro-ADAMTS-5 in osteoarthritic (OA) cartilage, thus acti-
vating these aggrecanases. Recently, a single nucleotide polymorphism in
PCSK6, the gene that encodes PACE4, was reported to protect against pain
in subjects with radiographic knee OA. In addition, PCSK6 null mice are
resistant to acute pain in a battery of algesiometric assays, implying a
functional role for PACE4 in pain generation. Therefore, we decided to
evaluate the role of PACE4 inprogressionof joint pathologyand associated
pain-related behaviours in surgically induced murine osteoarthritis.
Methods: Destabilisation of the medial meniscus (DMM) surgery was
performed in the right knees of 10-week old male wild type (WT) or
PCSK6 null C57BL/6 mice. Mice were monitored bi-weekly for
mechanical allodynia in the hind paw as a pain-related behavior, using
von Frey ﬁbers and the up-down staircase technique. Sixteen weeks
after DMM, locomotive changes indicative of “movement-provoked
pain”, including distance traveled and climbing, were measured by
overnight monitoring on a LABORAS platform. At 16 weeks post DMM,
mice were taken down and knees were collected for histopathology
according to OARSI recommendations. In addition, 16 weeks after sur-
gery, mice were perfused transcardially with paraformaldehyde; the
spinal column was decalciﬁed prior to spinal cord sectioning of the L3–
L5 levels. Immunohistochemical staining with anti-Iba1 was used to
examine microglia in the dorsal horn. Quantiﬁcation of the number and
morphology of Iba1-immunoreactive microglia was performed
according to established methods in order to assess microglia activa-
tion, a process that is involved in maintenance of chronic pain.
Results: Joint histopathology at 16 weeks post DMM revealed a total
joint score of 22  1 in WT mice, and 23  4 in PCSK6 null mice.
Development and progression of mechanical allodynia after DMM
surgery was very similar in WT and in PCSK6 null mice: both strains of
mice developed allodynia in the ipsilateral hind paw by 4 weeks after
DMM, and this was maintained for 16 weeks.
Sixteen weeks after DMM, WT mice display locomotive changes indi-
cative of “movement-provoked pain”, including decreased climbing and
decreased distance travelled overnight. In contrast, PCSK6 null mice did
not show signs of decreased movement at 16 weeks post DMM. At that
time-point, the dorsal horn of the spinal cord (L3–L5) in WT mice
showed marked microglial activation, whereas this was not the case in
PCSK6 null mice. Since microgliosis has been correlated to chronic pain
in models of nerve injury, this may suggest that PCSK6 null mice do not
develop chronic pain in this OA model.Conclusions: In summary, by 16 weeks after DMM surgery, PCSK6 null
mice developed OA pathology to the same extent as WT mice. In
addition, knee joint pathology was associated with mechanical allo-
dynia after DMM surgery to the same extent as in WT mice. In contrast,
unlike WT mice, PCSK6 null mice did not develop locomotor changes
that are indicative of movement-provoked pain. This was associated
with the absence of microglia activation in the dorsal horn of the spinal
cord. These results further support earlier ﬁndings that PACE4 may play
a role in pain and justify further studies to analyze central mechanisms.
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PAIN PATHWAY ACTIVATION IN DORSAL ROOT GANGLIA AND
DORSAL HORN IN A MURINE SURGICAL MODEL OF OSTEOARTHRITIS
P.B. Tran y, R.E. Miller y, R.J. Miller z, A.-M. Malfait y. yRush Univ. Med. Ctr.,
Chicago, IL, United States; zNorthwestern Univ., Chicago, IL, United States
Purpose: In nerve injury models, maintenance of chronic pain
involves microglial activation in the dorsal horn (DH) of the spinal
cord. This is a dynamic process, which depends on signaling mole-
cules, such as the chemokine fractalkine (CX3CL1), which are pro-
duced in dorsal root ganglia (DRG) neurons and transported to the
DH, resulting in activation of DH microglia. We monitor pain and
associated pathways over a period of 16 weeks post destabilization
of the medial meniscus (DMM) surgery in the mouse. This model of
slowly progressive knee osteoarthritis is associated with changing
pain-related behaviors and concurrent molecular changes in the
innervating DRG over 16 weeks post surgery. Speciﬁcally, mice
develop progressive mechanical allodynia over the ﬁrst 4 weeks,
while locomotive changes indicative of chronic pain ﬁrst appear 8
weeks post DMM. The purpose of the current study was to inves-
tigate fractalkine expression in DRG neurons as well as microglial
activation in the DH over 16 weeks following DMM surgery.
Methods: DMM or sham surgery was performed in the right knees of
10-week old male C57BL/6 mice. Four, 8, and 16 weeks post DMM and
sham surgeries, L3-L5 DRGwere harvested and cells were cultured for 4
days; supernatants were collected for fractalkine ELISA. For immuno-
histochemistry, mice were perfused transcardially with paraformalde-
hyde, and the spinal column was decalciﬁed prior to cryosectioning. To
assess microglial activation in the DH, spinal cord sections were
immunostained with anti-Iba1 and quantiﬁcation of the number and
morphology of Iba1 immunoreactive microglia was performed
according to established methods. Microglia in which process length
was less than double soma diameter were classiﬁed as effector (i.e.,
activated) microglia while microglia in which process length was more
than double the soma diameter were classiﬁed as surveyor microglia.
Results: At 4 weeks post DMM surgery, cultured DRG cells released
similar amounts of fractalkine compared to age-matched naïve cells. At
8 weeks post surgery, DRG cells released elevated levels of fractalkine
protein compared to sham and age-matched naïve DRG cells (p < 0.01),
and by 16 weeks post surgery levels were still somewhat elevated in
DMM cells (p < 0.05), but less so than at 8 weeks.
The dorsal horn showed increased Iba1 expression at 8 and 16 weeks but
not at4weekspostDMMcompared toshamandage-matchednaïvemice.
